801 related articles for article (PubMed ID: 25453486)
21. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Spencer TJ; Greenbaum M; Ginsberg LD; Murphy WR
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):501-10. PubMed ID: 19877974
[TBL] [Abstract][Full Text] [Related]
22. Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison.
Joseph A; Ayyagari R; Xie M; Cai S; Xie J; Huss M; Sikirica V
Eur Child Adolesc Psychiatry; 2017 Aug; 26(8):875-897. PubMed ID: 28258319
[TBL] [Abstract][Full Text] [Related]
23. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
Faraone SV; McBurnett K; Sallee FR; Steeber J; López FA
Clin Ther; 2013 Nov; 35(11):1778-93. PubMed ID: 24139092
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study.
Iwanami A; Saito K; Fujiwara M; Okutsu D; Ichikawa H
BMC Psychiatry; 2020 Oct; 20(1):485. PubMed ID: 33008345
[TBL] [Abstract][Full Text] [Related]
25. Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
Signorovitch J; Erder MH; Xie J; Sikirica V; Lu M; Hodgkins PS; Wu EQ
Pharmacoepidemiol Drug Saf; 2012 May; 21 Suppl 2():130-7. PubMed ID: 22552988
[TBL] [Abstract][Full Text] [Related]
26. Extended Release Guanfacine in Pediatric Anxiety Disorders: A Pilot, Randomized, Placebo-Controlled Trial.
Strawn JR; Compton SN; Robertson B; Albano AM; Hamdani M; Rynn MA
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):29-37. PubMed ID: 28165762
[TBL] [Abstract][Full Text] [Related]
27. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
Sikirica V; Haim Erder M; Xie J; Macaulay D; Diener M; Hodgkins P; Wu EQ
Pharmacoeconomics; 2012 Aug; 30(8):e1-15. PubMed ID: 22788263
[TBL] [Abstract][Full Text] [Related]
28. Morning and Evening Effects of Guanfacine Extended Release Adjunctive to Psychostimulants in Pediatric ADHD.
Wilens TE; McBurnett K; Turnbow J; Rugino T; White C; Youcha S
J Atten Disord; 2017 Jan; 21(2):110-119. PubMed ID: 24071772
[TBL] [Abstract][Full Text] [Related]
29. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
[TBL] [Abstract][Full Text] [Related]
30. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
[TBL] [Abstract][Full Text] [Related]
31. Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study.
McCracken JT; McGough JJ; Loo SK; Levitt J; Del'Homme M; Cowen J; Sturm A; Whelan F; Hellemann G; Sugar C; Bilder RM
J Am Acad Child Adolesc Psychiatry; 2016 Aug; 55(8):657-666.e1. PubMed ID: 27453079
[TBL] [Abstract][Full Text] [Related]
32. Guanfacine extended-release: in attention deficit hyperactivity disorder.
Muir VJ; Perry CM
Drugs; 2010 Sep; 70(13):1693-702. PubMed ID: 20731476
[TBL] [Abstract][Full Text] [Related]
33. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Sallee FR; Lyne A; Wigal T; McGough JJ
J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):215-26. PubMed ID: 19519256
[TBL] [Abstract][Full Text] [Related]
34. Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD.
Huss M; Dirks B; Gu J; Robertson B; Newcorn JH; Ramos-Quiroga JA
Eur Child Adolesc Psychiatry; 2018 Oct; 27(10):1283-1294. PubMed ID: 29442229
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.
Dittmann RW; Cardo E; Nagy P; Anderson CS; Bloomfield R; Caballero B; Higgins N; Hodgkins P; Lyne A; Civil R; Coghill D
CNS Drugs; 2013 Dec; 27(12):1081-92. PubMed ID: 23959815
[TBL] [Abstract][Full Text] [Related]
36. Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine.
Molife C; Haynes VS; Nyhuis A; Faries DE; Gelwicks S; Kelsey DK; Alatorre CI
Curr Med Res Opin; 2018 Apr; 34(4):619-632. PubMed ID: 29298540
[TBL] [Abstract][Full Text] [Related]
37. Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
Rizzo R; Martino D
Expert Rev Neurother; 2015 Apr; 15(4):347-54. PubMed ID: 25800130
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents.
Childress A; Hoo-Cardiel A; Lang P
Expert Opin Pharmacother; 2020 Mar; 21(4):417-426. PubMed ID: 31971448
[No Abstract] [Full Text] [Related]
39. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
[TBL] [Abstract][Full Text] [Related]
40. An open-label study of guanfacine extended release for traumatic stress related symptoms in children and adolescents.
Connor DF; Grasso DJ; Slivinsky MD; Pearson GS; Banga A
J Child Adolesc Psychopharmacol; 2013 May; 23(4):244-51. PubMed ID: 23683139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]